Cargando…
Self-assembling synthetic nanoadjuvant scaffolds cross-link B cell receptors and represent new platform technology for therapeutic antibody production
Host antibody responses are pivotal for providing protection against infectious agents. We have pioneered a new class of self-assembling micelles based on pentablock copolymers that enhance antibody responses while providing a low inflammatory environment compared to traditional adjuvants. This type...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for the Advancement of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8336949/ https://www.ncbi.nlm.nih.gov/pubmed/34348905 http://dx.doi.org/10.1126/sciadv.abj1691 |
_version_ | 1783733407528779776 |
---|---|
author | Senapati, Sujata Darling, Ross J. Ross, Kathleen A. Wannemeuhler, Michael J. Narasimhan, Balaji Mallapragada, Surya K. |
author_facet | Senapati, Sujata Darling, Ross J. Ross, Kathleen A. Wannemeuhler, Michael J. Narasimhan, Balaji Mallapragada, Surya K. |
author_sort | Senapati, Sujata |
collection | PubMed |
description | Host antibody responses are pivotal for providing protection against infectious agents. We have pioneered a new class of self-assembling micelles based on pentablock copolymers that enhance antibody responses while providing a low inflammatory environment compared to traditional adjuvants. This type of “just-right” immune response is critical in the rational design of vaccines for older adults. Here, we report on the mechanism of enhancement of antibody responses by pentablock copolymer micelles, which act as scaffolds for antigen presentation to B cells and cross-link B cell receptors, unlike other micelle-forming synthetic block copolymers. We exploited this unique mechanism and developed these scaffolds as a platform technology to produce antibodies in vitro. We show that this novel approach can be used to generate laboratory-scale quantities of therapeutic antibodies against multiple antigens, including those associated with SARS-CoV-2 and Yersinia pestis, further expanding the value of these nanomaterials to rapidly develop countermeasures against infectious diseases. |
format | Online Article Text |
id | pubmed-8336949 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | American Association for the Advancement of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-83369492021-08-12 Self-assembling synthetic nanoadjuvant scaffolds cross-link B cell receptors and represent new platform technology for therapeutic antibody production Senapati, Sujata Darling, Ross J. Ross, Kathleen A. Wannemeuhler, Michael J. Narasimhan, Balaji Mallapragada, Surya K. Sci Adv Research Articles Host antibody responses are pivotal for providing protection against infectious agents. We have pioneered a new class of self-assembling micelles based on pentablock copolymers that enhance antibody responses while providing a low inflammatory environment compared to traditional adjuvants. This type of “just-right” immune response is critical in the rational design of vaccines for older adults. Here, we report on the mechanism of enhancement of antibody responses by pentablock copolymer micelles, which act as scaffolds for antigen presentation to B cells and cross-link B cell receptors, unlike other micelle-forming synthetic block copolymers. We exploited this unique mechanism and developed these scaffolds as a platform technology to produce antibodies in vitro. We show that this novel approach can be used to generate laboratory-scale quantities of therapeutic antibodies against multiple antigens, including those associated with SARS-CoV-2 and Yersinia pestis, further expanding the value of these nanomaterials to rapidly develop countermeasures against infectious diseases. American Association for the Advancement of Science 2021-08-04 /pmc/articles/PMC8336949/ /pubmed/34348905 http://dx.doi.org/10.1126/sciadv.abj1691 Text en Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC). https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial license (https://creativecommons.org/licenses/by-nc/4.0/) , which permits use, distribution, and reproduction in any medium, so long as the resultant use is not for commercial advantage and provided the original work is properly cited. |
spellingShingle | Research Articles Senapati, Sujata Darling, Ross J. Ross, Kathleen A. Wannemeuhler, Michael J. Narasimhan, Balaji Mallapragada, Surya K. Self-assembling synthetic nanoadjuvant scaffolds cross-link B cell receptors and represent new platform technology for therapeutic antibody production |
title | Self-assembling synthetic nanoadjuvant scaffolds cross-link B cell receptors and represent new platform technology for therapeutic antibody production |
title_full | Self-assembling synthetic nanoadjuvant scaffolds cross-link B cell receptors and represent new platform technology for therapeutic antibody production |
title_fullStr | Self-assembling synthetic nanoadjuvant scaffolds cross-link B cell receptors and represent new platform technology for therapeutic antibody production |
title_full_unstemmed | Self-assembling synthetic nanoadjuvant scaffolds cross-link B cell receptors and represent new platform technology for therapeutic antibody production |
title_short | Self-assembling synthetic nanoadjuvant scaffolds cross-link B cell receptors and represent new platform technology for therapeutic antibody production |
title_sort | self-assembling synthetic nanoadjuvant scaffolds cross-link b cell receptors and represent new platform technology for therapeutic antibody production |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8336949/ https://www.ncbi.nlm.nih.gov/pubmed/34348905 http://dx.doi.org/10.1126/sciadv.abj1691 |
work_keys_str_mv | AT senapatisujata selfassemblingsyntheticnanoadjuvantscaffoldscrosslinkbcellreceptorsandrepresentnewplatformtechnologyfortherapeuticantibodyproduction AT darlingrossj selfassemblingsyntheticnanoadjuvantscaffoldscrosslinkbcellreceptorsandrepresentnewplatformtechnologyfortherapeuticantibodyproduction AT rosskathleena selfassemblingsyntheticnanoadjuvantscaffoldscrosslinkbcellreceptorsandrepresentnewplatformtechnologyfortherapeuticantibodyproduction AT wannemeuhlermichaelj selfassemblingsyntheticnanoadjuvantscaffoldscrosslinkbcellreceptorsandrepresentnewplatformtechnologyfortherapeuticantibodyproduction AT narasimhanbalaji selfassemblingsyntheticnanoadjuvantscaffoldscrosslinkbcellreceptorsandrepresentnewplatformtechnologyfortherapeuticantibodyproduction AT mallapragadasuryak selfassemblingsyntheticnanoadjuvantscaffoldscrosslinkbcellreceptorsandrepresentnewplatformtechnologyfortherapeuticantibodyproduction |